Lupin launches Amabelz tablets in US market
New Delhi : Drug major Lupin said it has launched Amabelz tablets, used in prevention of postmenopausal osteoporosis, in the American market after getting approval from the US health regulator.
Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched Amabelz tablets, a generic version of Amneal Pharmaceuticals' Activella tablets in the US, Lupin said in a statement.
The company's product is indicated in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.
According to IMS MAT sales data, Activella had US sales of USD 91.1 million.
Shares of Lupin ended 1.37 per cent down at Rs 1,440.20 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd